EP3323807A1 — Prolyl hydroxylase inhibitors and methods of use
Assigned to Akebia Therapeutics Inc · Expires 2018-05-23 · 8y expired
What this patent protects
The present invention provides a compound having the formula (I): wherein R is selected from 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl; R 6 is hydrogen, methyl, or ethyl; or a pharmaceutically acceptable salt thereof. The compound is for use in methods for treating, …
USPTO Abstract
The present invention provides a compound having the formula (I): wherein R is selected from 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl; R 6 is hydrogen, methyl, or ethyl; or a pharmaceutically acceptable salt thereof. The compound is for use in methods for treating, inter alia, peripheral vascular disease, coronary artery disease or heart failure, for increasing blood flow, oxygen delivery or energy utilization in ischemic tissues, for controlling the proliferation and differentiation of erythroid progenitor cells into red blood cells, for alleviating the adverse consequences of hypertension or diabetes or for increasing stimulus of vasodilation, vascular permeability, or endothelial cell migration and proliferation.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.